BCLI SPA in Place for Phase 3b Trial of NurOwn in ALS
BCLI Stock | USD 1.73 0.02 1.17% |
Under 62% of Brainstorm Cell's investor base is looking to short. The analysis of the overall investor sentiment regarding Brainstorm Cell Therapeutics suggests that many traders are alarmed. Brainstorm Cell's investing sentiment shows overall attitude of investors towards Brainstorm Cell Therapeutics.
Brainstorm |
By David Bautz, PhD NASDAQBCLI READ THE FULL BCLI RESEARCH REPORT Business Update Ready to Move Ahead with Phase 3b Trial for NurOwn in ALS On July 8, 2024, BrainStorm Cell Therapeutics, Inc. conducted a conference call to provide an update on the companys NurOwn program. The company is currently preparing for a Phase 3b clinical trial of NurOwn in patients with amyotrophic
Read at finance.yahoo.com
Brainstorm Cell Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Brainstorm Cell can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Brainstorm Cell Fundamental Analysis
We analyze Brainstorm Cell's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Brainstorm Cell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Brainstorm Cell based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Brainstorm Cell is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Brainstorm Cell Ther Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Brainstorm Cell stock to make a market-neutral strategy. Peer analysis of Brainstorm Cell could also be used in its relative valuation, which is a method of valuing Brainstorm Cell by comparing valuation metrics with similar companies.
Peers
Brainstorm Cell Related Equities
TERN | Terns Pharmaceuticals | 3.41 | ||||
GRI | GRI Bio | 3.08 | ||||
CNTB | Connect Biopharma | 2.78 | ||||
EWTX | Edgewise Therapeutics | 1.33 | ||||
CRVS | Corvus Pharmaceuticals | 0.36 | ||||
CELC | Celcuity LLC | 0.71 | ||||
ALDX | Aldeyra | 1.66 | ||||
PLX | Protalix Biotherapeutics | 1.80 | ||||
DAWN | Day One | 1.81 | ||||
MREO | Mereo BioPharma | 2.20 | ||||
CUE | Cue Biopharma | 2.56 | ||||
TRVI | Trevi Therapeutics | 2.80 | ||||
GBIO | Generation Bio | 3.52 | ||||
BCAB | Bioatla | 4.79 | ||||
HOWL | Werewolf Therapeutics | 5.10 | ||||
XFOR | X4 Pharmaceuticals | 5.13 | ||||
CCCC | C4 Therapeutics | 5.58 | ||||
INZY | Inozyme Pharma | 6.09 | ||||
ANTX | AN2 Therapeutics | 6.25 | ||||
CKPT | Checkpoint Therapeutics | 6.26 | ||||
HCWB | HCW Biologics | 9.80 | ||||
PASG | Passage Bio | 11.88 |
Complementary Tools for Brainstorm Stock analysis
When running Brainstorm Cell's price analysis, check to measure Brainstorm Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brainstorm Cell is operating at the current time. Most of Brainstorm Cell's value examination focuses on studying past and present price action to predict the probability of Brainstorm Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Brainstorm Cell's price. Additionally, you may evaluate how the addition of Brainstorm Cell to your portfolios can decrease your overall portfolio volatility.
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
CEOs Directory Screen CEOs from public companies around the world | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Global Correlations Find global opportunities by holding instruments from different markets |